Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Pharmaceuticals (CASI) over the last 5 years, with Q2 2025 value amounting to $31.2 million.

  • Pharmaceuticals' Liabilities and Shareholders Equity rose 6075701.47% to $31.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $85.0 million, marking a year-over-year decrease of 3627.25%. This contributed to the annual value of $53.7 million for FY2024, which is 2868.95% down from last year.
  • Latest data reveals that Pharmaceuticals reported Liabilities and Shareholders Equity of $31.2 million as of Q2 2025, which was up 6075701.47% from $40821.0 recorded in Q1 2025.
  • Over the past 5 years, Pharmaceuticals' Liabilities and Shareholders Equity peaked at $138.3 million during Q4 2021, and registered a low of $40821.0 during Q1 2025.
  • Over the past 5 years, Pharmaceuticals' median Liabilities and Shareholders Equity value was $53.7 million (recorded in 2024), while the average stood at $50.3 million.
  • Data for Pharmaceuticals' Liabilities and Shareholders Equity shows a peak YoY increase of 6075701.47% (in 2025) and a maximum YoY decrease of 9992.96% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Pharmaceuticals' Liabilities and Shareholders Equity stood at $138.3 million in 2021, then crashed by 30.42% to $96.2 million in 2022, then decreased by 21.79% to $75.3 million in 2023, then decreased by 28.69% to $53.7 million in 2024, then tumbled by 41.87% to $31.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $31.2 million in Q2 2025, compared to $40821.0 in Q1 2025 and $53.7 million in Q4 2024.